Business
Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study
The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At this congress, the final OS analysis from the pivotal study (OptiTROP-Lung03) of sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®), a TROP2 ADC developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK), has been selected as a Late-Breaking Abstract (LBA) (Presentation Number: LBA4). Professor Yunpeng Ya
About this update from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
[{"type":"text","content":"CHENGDU, China, March 18, 2026 /PRNewswire/ -- The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At this congress, the final OS analysis from the pivotal study (OptiTROP-Lung03) of sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®), a TROP2 ADC developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK), has been selected as a Late-Breaking Abstract (LBA) (Presentation Number: LBA4). Professor Yunpeng Yang from the Sun Yat-sen University Cancer Center will present the findings to the global research community during a Mini Oral Session. The abstract was published on the ESMO Open.","length":752,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":91,"url":"https://media.zenfs.com/en/prnewswire.com/d7fe4341dbe314250b9f20b1a6a88918"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hOs2dbPo3aksHP6KJOMQZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d7fe4341dbe314250b9f20b1a6a88918","width":400,"height":91}},"href":"https://mma.prnewswire.com/media/2937016/1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The OptiTROP-Lung03 study was designed to evaluate the efficacy and safety profile of sac-TMT monotherapy (5 mg/kg every other week) versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have previously treated with an EGFR-TKI and platinum-based chemotherapy. Previously reported results presented at the ASCO 2025 meeting in 137 randomized participants demonstrated that sac-TMT achieved statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared to docetaxel——the hazard ratio (HR) for BICR-assessed PFS was 0.30 (95% CI: 0.20–0.46, one-sided p<0.001) and HR for OS was 0.49 (95% CI: 0.27–0.88, one-sided p=0.007)[1]. Based on these positive results, sac-TMT received approval from the National Medical Products Administration (NMPA) for this indication, which has also been included in China's National Reimbursement Drug List (NRDL).","length":972,"tagName":...
More updates from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H